



The Company Announcements Platform
ASX Limited
By E-lodgment

18 May 2016

PTX SECURES \$7.0 M CAPITAL RAISING

- **\$7.0 M institutional placement**
- **Rights issue on same terms to raise up to a further \$3.4 M**

18 May 2016, Melbourne, Australia: Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company, is pleased to advise the successful completion of an institutional placement to raise \$7.0 million.

The placement, largely to life-science focused Australian institutional investors, has been undertaken which will involve the issue of approximately 77.7 million shares at 9.0 cents per share with 1 attaching option for every 2 shares subscribed (exercisable at 18 cents; expiring 30 June 2018). The placement will be undertaken in two tranches. The first tranche of approximately 19.4 million shares will be unconditional, with shareholders to approve the second tranche (of approximately 58.3 million) and all attaching options.

PTX also announced that it will offer existing shareholders the opportunity to participate on the same terms as the placement via a 1 for 3 non-renounceable rights issue, also at 9.0 cents per share with an attaching 1 for 2 option (exercisable at 18 cents; expiring 30 June 2018), to raise up to an additional circa \$3.4 million. Eligible shareholders must be on the Company's share register on the record date on Thursday 26 May 2016.

PTX's CEO, Steven Yatomi-Clarke said, "We are delighted with the caliber of investors we have attracted in this capital raising. They represent some of the most sophisticated biotech institutional investors in Australia today and reflect the fact that PTX has one of the most advanced and prospective clinical-stage pipelines on the ASX, with three Phase 1b/2 clinical trials in breast cancer, ovarian cancer and acute myeloid leukemia (AML) at prestigious US medical institutions."

PTX Chairman, Steven Engle said, "This represents strong validation of the Company's robust science and clinical programs and provides us with the resources to immediately move ahead with our promising Akt inhibitor for AML at Moffitt Cancer Centre in Florida. This is in addition to continuing our other Phase 1b/2 programs in ovarian and breast cancer."

"We warmly welcome this outstanding group of investors as shareholders in PTX during a time of real operational momentum."



Overview of the Placement

Prescient Therapeutics Limited (**Prescient** or the **Company**) is pleased to announce that it has agreed to issue 77.7 million fully paid ordinary shares (**Placement Shares**) at \$0.09 (9 cents) per share (**Placement**) to raise approximately \$7.0 million.

The Placement will be conducted in two tranches, with the first tranche utilising the Company's existing placement capacity under the Listing Rules (**Tranche 1 Shares**), and the second tranche being subject to shareholder approval (**Tranche 2 Shares**).

Applicants who subscribe under the Placement will also receive one option for every two Shares subscribed for, exercisable at 18 cents per share and expiring on 30 June 2018 (**Options**). Prescient will seek to have the Options quoted on ASX. All Options attaching to the Placement are subject to shareholder approval.

Overview of the Rights Issue

Prescient is also pleased to announce a pro-rata non-renounceable rights issue (**Rights Issue**) of ordinary shares in the Company (**Shares**) on a 1-for-3 basis at an issue price of \$0.09 per Share, and 1 free New Option for every 2 New Shares subscribed for under the Rights Issue with an exercise price of 18 cents per New Option and exercisable on 30 June 2016 (**Rights Issue**). The Rights Issue will be made to holders of Shares with a registered address in Australia or New Zealand as at 7:00pm (Melbourne time) on Thursday, 26 May 2016 (**Record Date**) (**Eligible Shareholders**).

Pursuant to the Rights Issue, which offers Eligible Shareholders the right to take up 1 new Share for every 3 Share held as at the Record Date (**Entitlement**), the Company intends to issue up to 37,728,703 New Shares at an issue price of \$0.09 each (**New Shares**), and up to 18,864,352 New Options on a 1-for-2 basis to raise up to \$3,395,583 (before costs).

The Entitlement to subscribe for New Shares under the Rights Issue will be non-renounceable and offered to Eligible Shareholders. The Rights Issue is not underwritten.

The New Shares issued under the Rights Issue will be fully paid ordinary shares and will rank equally with the Company's existing Shares on issue. The Company will apply for the grant by ASX for official quotation of the New Shares.

A Prospectus in relation to the Rights Issue has been lodged with ASX and will be dispatched with an Entitlement and Acceptance Form will be despatched to Eligible Shareholders in accordance with the timetable below.

Number of Shares to be issued

The number of issued Shares at the date of this announcement and the maximum total number of issued Shares following the Placement and Rights Issue are as follows:

EVENT	NUMBER OF SHARES
Shares on issue at date of this announcement	93,741,665
New Shares proposed to be issued pursuant to Tranche 1 Placement	19,444,445
New Shares proposed to be issued pursuant to Tranche 2 Placement (subject to shareholder approval)	58,333,335
New Shares proposed to be issued pursuant to the Rights Issue	37,728,703
Total Shares on issue after completion of the Offer and Placement	209,248,148

Use of Funds

Use of funds will be applied towards progressing Prescient's clinical programs, including additional drug manufacture and clinical trial management, funding the costs associated with the capital raising and for working capital purposes. As the Rights Issue is not underwritten, the allocation of the funds raised as part of the Rights Issue may depend on the level of acceptances and the amount of Application Monies received.

Placement and Rights Issue indicative timetable

Event	Date
Announcement of Rights Issue	Wednesday 18 May 2016
The Company to give an Appendix 3B to the ASX and lodge the Prospectus with ASIC	Wednesday 18 May 2016
Dispatch and announce notice of general meeting	Wednesday 18 May 2016
The Company to send notice to Eligible Shareholders containing information required by Appendix 3B	Thursday 19 May 2016
Issue date for first tranche placement (Appendix 3B and 708A cleansing notice)	Tuesday 24 May 2016
"Ex date" - the date on which Shares are quoted ex-Entitlement	Wednesday 25 May 2016
"Record Date" - the date for determining entitlements of Eligible Shareholders to participate in the Rights Issue (7.00pm Melbourne time)	Thursday 26 May 2016 (7:00pm Sydney time)
Anticipated dispatch of offer materials and Entitlement and Acceptance Form to Shareholders (and announcement to ASX that this has occurred)	Tuesday 31 May 2016
Last day to extend the Applications Closing Date	Thursday 16 June 2016
Last date for receipt of Entitlement and Acceptance Forms and payment (Applications Closing Date) (5:00pm Melbourne time)	Tuesday 21 June 2016 (5:00pm Sydney time)
New Shares quoted on a deferred settlement basis	Wednesday 22 June 2016
The Company to notify ASX of under subscriptions	Wednesday 22 June 2016
EGM to approve second tranche placement (and options)	Wednesday 22 June 2016
Issue date for second tranche placement plus options (Appendix 3B and 708A cleansing notice)	Thursday 23 June 2016
The Company to issue New Shares under the Rights Issue Offer	Thursday 23 June 2016
Normal trading commences and Dispatch of Holding Statements	Friday 24 June 2016

This timetable is indicative only and subject to change. The Company reserves the right, subject to the Corporations Act, ASX Listing Rules and other applicable laws to vary the dates of the Placement and the Rights Issue and Shortfall Offer, without prior notice.



The Company also reserves the right not to proceed with the whole or part of the Placement and Right Issue Offer at any time prior to the issue date. In that event, application monies will be refunded in full without interest.

Full details of the terms and conditions of the Right Issue are contained in the Prospectus lodged with ASX and which will be despatched to Eligible Shareholders in accordance with the timetable set out above.

Further Inquiries:

Steven Yatomi-Clarke
CEO & Managing Director
Cell: +61 417 601 440
steven@ptxtherapeutics.com

ENDS

About Prescient Therapeutics Limited (PTX)

PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

PTX's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other attempts at Akt inhibition, which are non-specific kinase inhibitors that encounter toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and at Florida's H. Lee Moffitt Cancer Center (Moffitt). A Phase 1b/2 trial of the compound in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt. In addition, PTX has recently received IND allowance for a Phase 1b/2 trial evaluating PTX-200 as a new therapy for Acute Myeloid Leukemia.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors.